Associations - ER D538G

ER D538G ER D538G	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	H3B-6545 Sensitive: C2 – Inclusion Criteria
ER D538G ER D538G	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials
ER D538G ER D538G	Breast Cancer Breast Cancer	tamoxifen + fulvestrant Sensitive: C4 – Case Studies
ER D538G ER D538G	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	abemaciclib Sensitive: C4 – Case Studies
ER D538G ER D538G	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	palbociclib Resistant: C4 – Case Studies
ER D538G ER D538G	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	AZD9833 Sensitive: D – Preclinical
ER D538G ER D538G	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	lasofoxifene Sensitive: D – Preclinical
ER D538G ER D538G	Breast Cancer Breast Cancer	AZD9496 Sensitive: D – Preclinical

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and